Advertisement

Clinical MedicineIn-Press PreviewInfectious diseaseVaccines Free access | 10.1172/JCI146221

Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice

Sara A. Healy,1 Charles F. Anderson,1 Bruce J. Swihart,1 Agnes Mwakingwe-Omari,1 Erin E. Gabriel,2 Hope Decederfelt,3 Charlotte V. Hobbs,1 Kelly M. Rausch,1 Daming Zhu,1 Olga Muratova,1 Raul Herrera,1 Puthupparampil V. Scaria,1 Nicholas J. MacDonald,1 Lynn E. Lambert,4 Irfan Zaidi,4 Camila H. Coelho,1 Jonathan P. Renn,1 Yimin Wu,1 David L. Narum,1 and Patrick E. Duffy1

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Healy, S. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Anderson, C. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Swihart, B. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Mwakingwe-Omari, A. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Gabriel, E. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Decederfelt, H. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Hobbs, C. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Rausch, K. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Zhu, D. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Muratova, O. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Herrera, R. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Scaria, P. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by MacDonald, N. in: JCI | PubMed | Google Scholar |

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Lambert, L. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Zaidi, I. in: JCI | PubMed | Google Scholar |

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Coelho, C. in: JCI | PubMed | Google Scholar |

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Renn, J. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Wu, Y. in: JCI | PubMed | Google Scholar

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Narum, D. in: JCI | PubMed | Google Scholar |

1Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

2Department of Medical Epidemiology and Biostatistics, Karolinska Insitute, Stockholm, Sweden

3Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, United States of America

4Laboratory for Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America

Find articles by Duffy, P. in: JCI | PubMed | Google Scholar |

Published February 9, 2021 - More info

J Clin Invest. https://doi.org/10.1172/JCI146221.
Copyright © 2021, American Society for Clinical Investigation
Published February 9, 2021 - Version history
View PDF
Abstract

Background. Vaccines that block human-to-mosquito Plasmodium transmission are needed for malaria eradication and clinical trials have targeted zygote antigen Pfs25 for decades. We reported that a Pfs25 protein-protein conjugate vaccine formulated in alum adjuvant induced significant serum functional activity in both US and Malian adults. However, antibody titers declined rapidly, and transmission-reducing activity required four vaccine doses. Functional immunogenicity and durability must be improved before advancing TBV further in clinical development. We hypothesized that the pre-fertilization protein Pfs230 alone or in combination with Pfs25 would improve functional activity.Methods. Transmission-blocking vaccine candidates based on gamete antigen Pfs230 or Pfs25 were conjugated with Exoprotein A, formulated in Alhydrogel, and administered to mice, rhesus macaques, and humans. Antibody titers were measured by ELISA and transmission-reducing activity was assess by the Standard Membrane Feeding Assay. Results. Pfs25-EPA/Alhydrogel and Pfs230D1-EPA/Alhydrogel induced similar serum functional activity in mice, but Pfs230D1-EPA induced significantly greater activity in rhesus monkeys that was enhanced by complement. In U.S. adults, two vaccine doses induced complement-dependent activity in 4 of 5 Pfs230D1-EPA/Alhydrogel recipients but no significant activity in five Pfs25-EPA recipients, and combination with Pfs25-EPA did not increase activity over Pfs230D1-EPA alone.Conclusion. The complement-dependent functional immunogenicity of Pfs230D1-EPA represents a significant improvement over Pfs25-EPA in this comparative study. The rhesus model is more predictive of the functional human immune response to Pfs230D1 than is the mouse model. Trial Registration. ClinicalTrials.gov NCT02334462Funding. This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Supplemental material

View

Version history
  • Version 1 (February 9, 2021): In-Press Preview
Advertisement
Advertisement